TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A real-world study of 186 attendees at a brain health service in Monza, Italy, found that many people with subjective cognitive decline had modifiable dementia risk factors. Among those with available blood tests, elevated p-Tau217 was linked to signs of neurodegeneration; about 60% of participants who received results said they felt more motivated to make lifestyle changes. The findings do not show that biomarker disclosure prevents dementia or establish that people with memory concerns have Alzheimer’s disease.
A study of 186 attendees at a brain health service in Monza, Italy, found a substantial burden of modifiable dementia risk factors among people reporting memory or other cognitive changes despite normal standard test performance. The researchers also linked above-threshold blood p-Tau217 to signs of neurodegeneration in some participants, while about 60% of those given results reported greater motivation to change their lifestyle. The findings describe one service’s attendees; they do not establish that a positive biomarker means a person has dementia or that sharing results prevents it.
The paper, published in Neurological Sciences, examined consecutive attendees at a Brain Health Service in Monza. Of the 186 people included, 132 had subjective cognitive decline (SCD): they noticed changes in their cognition but continued to perform normally on standard cognitive tests. The service also assessed people with mild cognitive impairment, functional cognitive decline and people worried about their cognition without identified impairment.
For SCD participants with available plasma results, researchers grouped people according to whether p-Tau217 was at or above the study’s 0.15 pg/mL threshold or below it. The study reported signs of neurodegeneration among those above the threshold. The researchers also considered factors including cognitive testing, other clinical information and, where available, biomarkers and imaging. The report describes these group findings as exploratory, in part because of the study’s limited size.
At a second visit, participants were told their p-Tau217 and APOE genotype results and given an estimate of dementia risk, alongside suggestions for targeted prevention. The estimate combined a relative-risk measure based on the Lancet Commission’s risk factors with an age-related baseline calculated using the Brookmeyer method and Italian mortality data. One week after disclosure, participants completed online self-report questionnaires. About 60% of those who underwent disclosure said it had increased their motivation to make lifestyle changes; that response measures reported motivation, not later behavior or a change in dementia incidence.
Memory Concerns Beyond Test Scores
The results point to a gap between what a short cognitive test captures and what a person may report about their everyday thinking. SCD is not itself a diagnosis of dementia, and it can arise for varied reasons, but it may prompt a broader conversation about health and risk. The study suggests that a prevention-focused service can assess more than test performance, including modifiable factors that clinicians and patients may be able to address.
Biomarker disclosure is a separate and more unsettled issue. A blood marker associated with Alzheimer’s-related biology may help characterize risk, but it does not by itself show when, or whether, symptoms will develop. The finding that some participants reported greater motivation after receiving results may inform how services communicate risk. It does not establish that disclosure caused lasting lifestyle changes or improved health outcomes.
For readers, the distinction matters: memory concerns warrant context, not an automatic conclusion about Alzheimer’s disease. The study supports further evaluation of brain health services, while leaving open how well this approach works beyond one Italian service and how results should be used in routine care.
Products Worth Considering
Roborock Q7 M5+ Robot Vacuum and Mop
Dyson Purifier Hot+Cool HP1
Sonos Era 100 SL Compact Microphone-Free Speaker, Black
As an affiliate, we earn on qualifying purchases.
How Brain Health Services Assess Risk
Brain Health Services differ from conventional memory clinics in their emphasis on prevention and risk assessment as well as diagnosis. People may arrive by self-referral, through primary care or from a memory clinic. Assessments can include cognitive screening, blood biomarkers such as p-Tau217 and GFAP, APOE genotyping and brain imaging. People whose evaluation identifies mild cognitive impairment may be referred to a memory clinic.
Scientists and professional groups do not fully agree on how biomarker results should be used in people without measurable cognitive impairment. The source report says the 2024 Alzheimer’s Association criteria allow a biological definition of Alzheimer’s disease using validated abnormal biomarkers, regardless of cognitive status. However, the Association’s workgroup recommends against diagnostic biomarker testing in cognitively unimpaired people outside observational or therapeutic research. The International Working Group generally describes biomarker-positive, cognitively unimpaired people as being at risk, rather than diagnosing them with Alzheimer’s disease; it allows non-diagnostic risk assessment for people with SCD.
The study’s prevention rationale draws on the Lancet Commission’s estimate that addressing 14 modifiable risk factors could potentially prevent or delay up to 45% of dementia cases. That is a population-level estimate cited in the report, not a prediction that an individual can avoid dementia by changing particular habits.
“About 60% of participants who underwent disclosure reported greater motivation for lifestyle changes.”
— The study authors, as summarized by News-Medical
Limits of Biomarker Disclosure Evidence
The findings come from one service in Monza and an observational assessment of attendees, not a trial comparing disclosure with no disclosure. The available source does not establish how many people had usable p-Tau217 results for every analysis, whether participants followed the recommended preventive measures, or whether their motivation persisted beyond the one-week questionnaire.
It is also not clear from the reported results how accurately the 0.15 pg/mL threshold predicts future clinical decline in this particular population. Elevated p-Tau217 was linked to signs of neurodegeneration, but that association does not establish an individual prognosis. SCD can have multiple causes, and the study’s exploratory comparisons across clinical groups should not be treated as definitive profiles.
The broader question of whether and when to test people without measurable impairment remains disputed among expert groups. The report does not show that biomarker testing or disclosure should be adopted for everyone who reports memory concerns, nor that the approach reduces dementia rates.
Testing Prevention in Larger Studies
The immediate next step is further research on how brain health services identify risk and communicate results. Larger studies with follow-up would be needed to determine whether reported motivation leads to sustained changes, whether those changes affect measured risk, and how well biomarker thresholds predict later cognitive outcomes in people with SCD.
For now, the study adds real-world evidence to a debate over prevention-focused assessments and biomarker communication. Anyone concerned about memory changes can discuss them with a qualified health professional, who can consider the person’s symptoms and circumstances and advise whether further assessment is appropriate. The study itself does not provide a basis for diagnosing Alzheimer’s disease from a blood result alone.
Key Questions
What is subjective cognitive decline?
Subjective cognitive decline means a person notices changes in their memory or other thinking abilities while continuing to perform normally on standard cognitive tests. It is not, by itself, a diagnosis of dementia or Alzheimer’s disease.
Does elevated p-Tau217 mean someone has Alzheimer’s disease?
Not on the basis of this study alone. The researchers linked above-threshold p-Tau217 to signs of neurodegeneration in some participants, but the result does not establish an individual diagnosis or predict with certainty who will develop symptoms.
How many people said biomarker disclosure motivated lifestyle changes?
About 60% of participants who received disclosure reported greater motivation for lifestyle changes on a questionnaire completed one week later. The study did not establish whether they made lasting changes.
Does this study show that lifestyle changes prevent dementia?
No. The study examined risk factors and participants’ reported motivation; it did not test whether the recommended changes reduced dementia diagnoses. Its findings do not measure prevention outcomes.
Should everyone with memory concerns get a blood biomarker test?
The report does not support routine testing for everyone with memory concerns. Expert recommendations described in the article differ on biomarker use in people without measurable impairment. A qualified health professional can discuss an individual’s concerns and whether further assessment is suitable.
Source: rss
